Basking Ridge-based Regado Biosciences Inc. announced Wednesday the closing of its previously announced public offering.
According to the announcement, the gross proceeds to Regado from its sale of 10 million shares of its stock at a $6.00 price per share were approximately $60 million.
Regado expects to use the money to fund further clinical development of its lead product, REG1, and for working capital and other general corporate purposes, the announcement said.
Jefferies LLC, Deutsche Bank Securities and Cowen and Company LLC acted as joint bookrunning managers for the offering.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy